Notice of Completion of Acquisition of the Company's Own Shares

Japan, September 11, 2007 --- Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it completed acquisition of its own shares in the market, which was resolved by its Board of Directors on August 28, 2007.

Particulars

1. Class of shares acquired: Common stock of the Company
3. Total number of shares acquired: 8.3 million shares
4. Total value of acquisition: ¥ 43,088,442,000
5. Method of acquisition: Purchased on the Tokyo Stock Exchange and through ToSTNeT-2 (closing price transaction)

(Reference)
Resolution of the Board of Directors on August 28, 2007

1. Reasons for acquisition of its own shares: In order to improve capital efficiency and enhance returns to shareholders
2. Class of shares to be acquired: Common stock of the Company
3. Number of shares to be acquired: 8.3 million shares (maximum)
   (equivalent to 1.60% of a total of issued shares)
4. Aggregate amount of acquisition cost: ¥ 45 billion (maximum)

Contacts for inquiries or additional information

Astellas Pharma Inc.
Corporate Communications
Tel: +81-3-3244-3201 Fax: +81-3-5201-7473
http://www.astellas.com